淋巴瘤治疗迎来EZH2抑制剂他泽美司他
他泽美司他是首个获批用于滤泡性淋巴瘤的表观遗传治疗药物,通过抑制EZH2组蛋白甲基转移酶活性发挥作用。本文综述了EZH2突变在淋巴瘤发生中的功能研究、他泽美司他从临床前开发到获批用于复发FL的历程,以及未来在生发中心来源淋巴瘤中的潜在应用。
要点
- 他泽美司他是首个获批治疗滤泡性淋巴瘤的表观遗传药物。
- EZH2突变是FL和生发中心DLBCL中反复出现的突变。
- 他泽美司他抑制EZH2组蛋白甲基转移酶活性。
核心结论
- 他泽美司他是首个获批用于滤泡性淋巴瘤的表观遗传治疗药物。
研究设计与样本
- 本文为综述,讨论EZH2突变的功能研究及他泽美司他从临床前开发到获批的历程。
主要发现
- EZH2突变在滤泡性淋巴瘤和生发中心弥漫大B细胞淋巴瘤中反复出现。
- 他泽美司他通过抑制EZH2组蛋白甲基转移酶活性发挥作用。
临床怎么用
- 他泽美司他已获批用于治疗复发性滤泡性淋巴瘤。
- 未来可能扩大应用于生发中心来源的淋巴瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tazemetostat represents the first epigenetic therapy approved for the treatment of follicular lymphoma (FL). It inhibits the activity of the enhancer of zeste homolog 2 (EZH2) histone methyltransferase, the first of a multitude of epigenetic regulators that have been identified as recurrently mutated in FL and germinal center diffuse large B-cell lymphoma. In this review, we discuss the initial discovery and ongoing exploration of the functional role of EZH2 mutations in lymphomagenesis. We also explore the path from the preclinical development of tazemetostat to its approval for the treatment of relapsed FL, and potential future therapeutic applications. We discuss the clinical data that led to the approval of tazemetostat and ongoing research into the function of EZH2 and of tazemetostat in lymphomas that derive from the germinal center, which could increase the applicability of this drug in the future.
引用
- Morin RD, Arthur SE, Assouline S, et al. Treating lymphoma is now a bit EZ-er. Blood Adv. 2021. PMID: 33904892. doi:10.1182/bloodadvances.2020002773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。